<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04277403</url>
  </required_header>
  <id_info>
    <org_study_id>HIPSTER_2020</org_study_id>
    <nct_id>NCT04277403</nct_id>
  </id_info>
  <brief_title>HA-WBRT vs SRS in Patients With Multiple Brain Metastases</brief_title>
  <acronym>HipSter</acronym>
  <official_title>Hippocampal Avoidance Whole Brain Radiotherapy (HA-WBRT) and Stereotactic Radiosurgery (SRS) in Patients With Multiple Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the effectiveness and safety of two radiation treatment techniques for&#xD;
      patients with multiple brain metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients suffering from multiple brain metastases whole brain radiation therapy still&#xD;
      constitutes a standard therapy. However, because of the risk of neurocognitive side effects&#xD;
      as well as reduced local tumor control, employment of stereotactic radiosurgery (SRS) is&#xD;
      becoming more common. The disadvantage of SRS alone may be poor intracranial tumor control&#xD;
      because of frequent appearance of new distant brain metastases after therapy. In recent years&#xD;
      hippocampal avoidance whole brain therapy has been shown to minimize treatment related side&#xD;
      effects while reducing the rate of distant intracranial failure.&#xD;
&#xD;
      In this study patients will be randomized to receive either hippocampal avoidance whole brain&#xD;
      radiation therapy with integrated tumor boost (HA-WBRT+SIB) or stereotactic radiosurgery. The&#xD;
      investigators hypothesize that HA-WBRT+SIB can improve intracranial tumor control compared to&#xD;
      stereotactic radiosurgery, while avoiding additional neurocognitive side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>Observer-blinding</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intracranial Progression free survival</measure>
    <time_frame>up to 18 months</time_frame>
    <description>survival with freedom from both local and distant intracranial progression, measured in months from end of treatment until progression or death, assessed in follow-up imaging (MRI, FET-PET)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive function assessed by VLMT</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Change of z-scores of VLMT (Verbaler Lern- und Merkfähigkeitstest) to baseline examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive function assessed by COWAT</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Change of z-scores of COWAT (controlled oral word association test) to baseline examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive function assessed by TMT</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Change of z-scores of TMT (trail making test) to baseline examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control rate</measure>
    <time_frame>up to 18 months</time_frame>
    <description>rate of progression of treated metastases assessed in follow-up imaging (MRI, FET-PET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival time</measure>
    <time_frame>up to 18 months</time_frame>
    <description>time from end of treatment to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Score assessed by EORTC QLQ-C30 questionnaire</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Change in Quality of Life Score of EORTC QLQ-C30 (Quality of life core module) relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Score assessed by QLQ-BN20 questionnaire</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Change in Quality of Life Score of QLQ-BN20 (quality of life brain cancer module) relative to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>HA-WBRT+SIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a simultaneously integrated boost (SIB) to each brain metastasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hippocampal Avoiding Whole Brain Radiation Therapy with Simultaneous Integrated Boost</intervention_name>
    <description>Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a prescribed dose of 30Gy in 12 fractions, 2.5Gy per fraction and a simultaneously integrated boost (SIB) to each brain metastasis of 51Gy to 95% of PTV in 12 Fractions, 4.25Gy per fraction.</description>
    <arm_group_label>HA-WBRT+SIB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Single session or hypofractionated stereotactic radiosurgery</intervention_name>
    <description>Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases. Single session SRS will be delivered in 18 to 22Gy to the tumour encompassing 80% Isodose. Hypofractionated stereotactic radiosurgery (HfSRS) will be delivered in 5 sessions of 6Gy each to the tumour encompassing 80% isodose.</description>
    <arm_group_label>SRS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 4 and not exceeding 15 brain metastases not exceeding a combined total volume&#xD;
             of 25ml and not previously treated with radiotherapy&#xD;
&#xD;
          -  KPI ≥ 70, ECOG ≤ 2&#xD;
&#xD;
          -  Age ≥ 18 years, Male or female&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neuroendocrine, SCLC, germinoma or lymphoma histology&#xD;
&#xD;
          -  Brain stem metastasis&#xD;
&#xD;
          -  Life expectancy &lt; 3 months&#xD;
&#xD;
          -  Suspicion of meningeosis carcinomatosa&#xD;
&#xD;
          -  Previous WBRT&#xD;
&#xD;
          -  Inability to participate in radiologic follow-up, contraindication to MR imaging (e.g.&#xD;
             not MRI compatible pacemaker, severe claustrophobia)&#xD;
&#xD;
          -  Inability to participate in neurocognitive function testing, insufficient German&#xD;
             language skills, aphasia, graphomotor impairment, insufficient vision, insufficient&#xD;
             attention span&#xD;
&#xD;
          -  Pregnancy, nursing or unwillingness to prevent pregnancy using effective methods of&#xD;
             contraception during treatment&#xD;
&#xD;
          -  Known abuse of medication, drugs or alcohol&#xD;
&#xD;
          -  Known severe dementia (z-score &lt; 2) or major cognitive function disorder that is not&#xD;
             caused by intracranial tumour&#xD;
&#xD;
          -  Known clinical depression or psychotic disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julian Mangesius, MD</last_name>
    <email>julian.mangesius@i-med.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Mangesius, MD</last_name>
      <email>julian.mangesius@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Ute Maria Ganswindt, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julian Mangesius, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brain metastases</keyword>
  <keyword>hippocampal avoidance</keyword>
  <keyword>radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

